For the twelve months ended Jun 30, 2026, Citius Pharmaceuticals Inc. reported -$54.33M of net income.
CTXR revenue was $1.49M in fiscal Q3 2026 (ended Jun 30, 2026), down 10.4% from the prior quarter. For the full fiscal 2022 it was $90.0K, up 0.0% from fiscal 2021. Compound annual growth was +12.5% over 5 years. It rose in 2 of the last 5 fiscal years. Fiscal 2022 is the highest of the 7 fiscal years on file.
CTXR net income was -$8.86M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$8.79M a year earlier. For the full fiscal 2025 it was -$37.43M, compared with -$40.19M in fiscal 2024.
CTXR diluted EPS was -$0.34 in fiscal Q3 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.38.
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $90.0K | $90.0K | $90.0K | $90.0K | $75.0K | $50.0K | - |
| Cost of revenue | - | - | - | - | - | - | - | $75.0K | $50.0K | $45.0K |
| Gross profit | - | - | - | - | - | - | - | $0 | $0 | - |
| Research and development | $9.16M | $11.91M | $14.82M | $17.66M | $12.24M | $8.81M | $125.0K | $6.56M | $2.94M | $2.93M |
| Selling, general and admin | $18.53M | $18.25M | $15.30M | $11.75M | $9.84M | $8.09M | $6.29M | $6.45M | $6.06M | $3.78M |
| Operating income | -$38.53M | -$42.00M | -$36.73M | -$33.32M | -$23.53M | -$17.71M | -$15.60M | -$13.79M | -$9.99M | -$7.45M |
| Interest expense | $267.8K | - | - | - | $10.8K | $15.7K | $16.4K | $15.8K | $850.8K | $9.0K |
| Pre-tax income | -$38.68M | -$38.85M | -$31.97M | -$33.06M | -$23.05M | -$17.55M | -$15.56M | $12.54M | $10.38M | -$8.30M |
| Income tax | $1.06M | $576.0K | $576.0K | $576.0K | $1.2K | $741 | - | - | - | - |
| Net income | -$37.43M | -$40.19M | -$33.69M | -$33.64M | -$23.05M | -$17.55M | -$15.56M | -$12.54M | -$10.38M | -$8.30M |
| EPS, basic | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | -$11.25 | -$19.25 | -$29.25 | -$47.25 | -$57.25 |
| EPS, diluted | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | -$11.25 | -$19.25 | -$29.25 | -$47.25 | -$57.25 |
| Diluted shares | 11.1M | 6.7M | 6.1M | 5.8M | 4.3M | 1.6M | 806,474.16 | 429,275 | 219,299.76 | 144,928.32 |
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.25M | $3.25M | $26.48M | $41.71M | $70.07M | $13.86M | $7.89M | $9.18M | $3.20M | $294.4K |
| Inventory | $22.29M | $8.27M | - | - | - | - | - | - | - | - |
| Current assets | $27.93M | $14.22M | $34.37M | $44.56M | $72.81M | $13.98M | $7.94M | $10.06M | $3.42M | $892.8K |
| Goodwill | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $1.59M | $1.59M | $1.59M |
| Total assets | $130.94M | $116.65M | $103.61M | $114.00M | $142.43M | $43.77M | $36.75M | $31.05M | $24.42M | $21.95M |
| Current liabilities | $44.91M | $35.81M | $5.78M | $4.53M | $3.98M | $4.10M | $4.61M | $3.18M | $2.47M | $5.18M |
| Total liabilities | $53.41M | $42.55M | $12.18M | $10.57M | $9.65M | $10.10M | $9.59M | - | - | - |
| Shareholders' equity | $67.55M | $74.10M | $91.43M | $103.43M | $132.78M | $33.67M | $27.15M | $30.64M | $21.95M | $16.77M |
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$24.25M | -$16.93M | -$12.44M | -$11.32M | -$7.97M | -$5.90M |
| Capital expenditures | - | - | - | - | $6.9K | $1.8K | - | - | $2.1K | - |
| Free cash flow | - | - | - | - | -$24.26M | -$16.93M | - | - | -$7.97M | - |
| Investing cash flow | -$5.75M | -$5.00M | - | - | -$40.01M | -$1.8K | - | - | -$2.1K | $255.7K |
| Financing cash flow | $33.30M | $9.97M | $13.83M | - | $120.47M | $22.90M | $11.15M | $17.30M | $10.88M | $5.26M |
| Stock-based compensation | $10.84M | $11.84M | $6.62M | $3.91M | $1.45M | $803.3K | $716.0K | $779.7K | $986.6K | $732.2K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | $2.6K | $1.3K |
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | 0.0% | 0.0% | 0.0% | 20.0% | 50.0% | - | - |
| Gross margin | - | - | - | - | - | - | - | 0.0% | 0.0% | - |
| Operating margin | - | - | - | -37017.8% | -26146.5% | -19678.5% | -17331.5% | -18385.5% | -19972.6% | - |
| Net margin | - | - | - | -37378.5% | -25616.0% | -19497.9% | -17291.3% | -16715.5% | -20769.9% | - |
| Free cash flow margin | - | - | - | - | -26952.6% | -18813.9% | - | - | -15946.7% | - |
| Return on equity | -55.4% | -54.2% | -36.9% | -32.5% | -17.4% | -52.1% | -57.3% | -40.9% | -47.3% | -49.5% |
| Return on assets | -28.6% | -34.4% | -32.5% | -29.5% | -16.2% | -40.1% | -42.4% | -40.4% | -42.5% | -37.8% |
| Current ratio | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $1.67M | $3.94M | - | - | - | - | - | - | - | - | - |
| Cost of revenue | $491.8K | $328.9K | $789.2K | - | - | - | - | - | - | - | - | - |
| Gross profit | $1.00M | $1.34M | $3.15M | - | - | - | - | - | - | - | - | - |
| Research and development | $1.05M | $1.63M | $1.60M | $1.64M | $1.62M | $3.77M | $2.13M | $2.91M | $2.76M | $3.61M | $2.62M | $2.88M |
| Selling, general and admin | $6.15M | $26.39M | $5.72M | $3.91M | $4.45M | $4.79M | $5.39M | $5.49M | $4.81M | $4.29M | $3.66M | $4.17M |
| Operating income | -$11.73M | -$32.19M | -$9.02M | -$8.44M | -$8.79M | -$11.26M | -$10.04M | -$11.05M | -$10.63M | -$10.97M | -$9.34M | -$10.12M |
| Interest expense | $198.3K | $33.0K | $155.5K | $95.5K | $172.3K | - | - | - | - | - | - | - |
| Pre-tax income | -$12.03M | -$28.34M | -$9.13M | -$8.48M | -$8.94M | -$11.25M | -$10.02M | -$10.93M | -$10.43M | -$8.40M | -$9.09M | -$9.80M |
| Income tax | -$107.3K | -$231.2K | $264.2K | $264.2K | $264.2K | $264.2K | $264.2K | $144.0K | $144.0K | $144.0K | $144.0K | $144.0K |
| Net income | -$8.86M | -$28.11M | -$9.39M | -$7.96M | -$8.79M | -$11.51M | -$10.28M | -$11.52M | -$10.89M | -$8.54M | -$9.23M | -$11.10M |
| EPS, basic | -$0.34 | -$0.95 | -$0.38 | - | -$0.80 | -$1.27 | -$1.30 | -$1.61 | -$1.57 | -$1.34 | -$1.45 | -$1.82 |
| EPS, diluted | -$0.34 | -$0.95 | -$0.38 | - | -$0.80 | -$1.27 | -$1.30 | -$1.61 | -$1.57 | -$1.34 | -$1.45 | -$1.82 |
| Diluted shares | 26.2M | 22.4M | 21.5M | - | 11.0M | 8.6M | 7.5M | - | 7.0M | 6.4M | 6.4M | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.01M | $4.59M | $7.72M | $4.25M | $6.09M | $26.4K | $1.10M | $3.25M | $17.91M | $12.56M | $20.35M | $26.48M |
| Receivables | $686.2K | $1.08M | $4.05M | - | - | - | - | - | - | - | - | - |
| Inventory | $22.63M | $22.66M | $22.64M | $22.29M | $17.21M | $15.34M | $14.38M | $8.27M | - | - | - | - |
| Current assets | $43.33M | $31.69M | $37.95M | $27.93M | $24.61M | $18.37M | $18.33M | $14.22M | $28.01M | $21.57M | $28.21M | $34.37M |
| Goodwill | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M |
| Total assets | $142.26M | $132.54M | $140.39M | $130.94M | $127.68M | $121.48M | $120.70M | $116.65M | $97.09M | $90.71M | $97.40M | $103.61M |
| Current liabilities | $51.65M | $55.02M | $38.21M | $44.91M | $51.84M | $49.88M | $44.81M | $35.81M | $4.15M | $4.17M | $5.58M | $5.78M |
| Total liabilities | $66.35M | $63.46M | $46.92M | $53.41M | $60.12M | $57.91M | $51.78M | $42.55M | $10.81M | $10.74M | $12.07M | $12.18M |
| Shareholders' equity | $66.61M | $69.08M | $93.47M | $67.55M | $67.56M | $63.58M | $68.92M | $74.10M | $86.28M | $79.97M | $85.33M | $91.43M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.68M | -$1.30M | -$13.01M | -$11.88M | -$5.41M | -$4.54M | -$4.73M | -$5.91M | -$8.37M | -$7.79M | -$6.14M | -$6.80M |
| Investing cash flow | -$2.00M | -$600.0K | -$4.40M | - | - | - | - | - | - | - | - | - |
| Financing cash flow | $23.09M | -$1.23M | $20.88M | $15.79M | $11.47M | $3.47M | $2.57M | -$3.75M | - | - | - | -$687 |
| Stock-based compensation | $3.81M | $3.79M | $4.28M | $2.89M | $2.72M | $2.70M | $2.52M | $2.64M | $3.06M | $3.08M | $3.06M | $3.08M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.1% | 80.3% | 80.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | -785.4% | -1931.0% | -228.7% | - | - | - | - | - | - | - | - | - |
| Net margin | -593.3% | -1685.9% | -238.2% | - | - | - | - | - | - | - | - | - |
| Current ratio | 0.84 | 0.58 | 0.99 | 0.62 | 0.47 | 0.37 | 0.41 | 0.40 | 6.75 | 5.17 | 5.06 | 5.95 |
Source: XBRL data Citius Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Aug 14, 2017; 1-for-25, first reported Dec 27, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CTXR | - | - | -$54.33M | - | $14.4M |
| PFE | $63.63B | +1.3% | $4.03B | 6.3% | $166.61B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| CPIX | $39.90M | -5.2% | -$10.92M | -27.4% | $80.5M |
| AYTU | $57.57M | -13.3% | -$14.25M | -24.8% | $19.5M |
| MESO | $120.25M | +599.2% | -$57.50M | -47.8% | $1.88B |